Prolactin and Male Sexual Function
Hyperprolactinemia, the Prolactinoma Workup, and Dopamine-Agonist Treatment
Evidence grade 4 of 5, Strong. Read how the Atlas grades evidence.
The written rationale for this grade is still being prepared.
- FDA
- N/A (endogenous hormone); cabergoline/bromocriptine are FDA-approved
Reference only. Not medical advice.
What can go wrong
Untreated macroprolactinoma can cause permanent vision loss and panhypopituitarism. Dopamine agonists are generally effective but carry their own risks: nausea, orthostatic hypotension, mood changes, impulse-control disorders (pathological gambling, hypersexuality), and, historically at the high doses used for Parkinson's, cardiac valvulopathy, prompting echocardiographic surveillance with long-term high-dose cabergoline. Drug-induced hyperprolactinemia may require coordinating with the prescribing specialist rather than stopping a needed medication.
This is something to take to a clinician. The Atlas can tell you what is known about prolactin and male sexual function in general. It cannot tell you what is happening in your body, and the difference matters most for exactly the symptoms that bring people to this page.
Prolactin is an anterior-pituitary hormone whose elevation is a classic, frequently missed cause of low libido, erectile dysfunction, and secondary hypogonadism in men. High prolactin suppresses GnRH (and thus LH/FSH and testosterone) and independently dampens sexual desire. The cause matters enormously: hyperprolactinemia can stem from medications (antipsychotics, some antidepressants, opioids), hypothyroidism, stress, or a pituitary tumor (prolactinoma), and in men prolactinomas are often LARGE (macroadenomas) by the time they present, threatening vision via the optic chiasm. Crucially, prolactin-secreting tumors are usually treated medically with dopamine agonists (cabergoline, bromocriptine), which shrink the tumor and normalize prolactin without surgery in most cases.
The hormone that can shut down libido and the whole axis at once, and the one TRT clinics too often forget to measure.
What people take it for
What it is taken for. Approval, where it exists, covers only some of these.
- Drug-induced
- Antipsychotics (risperidone, others), metoclopramide, opioids, some SSRIs raise prolactin
- Tumoral
- Prolactinoma (micro- or macroadenoma), the key surgical-risk lesion
- Other
- Primary hypothyroidism (high TRH stimulates prolactin), chronic kidney disease, stress, chest-wall stimulation
How it works
Prolactin is unusual in that it is under tonic INHIBITORY control by hypothalamic dopamine, so anything that lowers dopamine (dopamine-antagonist antipsychotics, for example) raises prolactin. Elevated prolactin suppresses kisspeptin/GnRH pulsatility, lowering LH/FSH and testosterone (a secondary hypogonadism), and also directly reduces sexual desire and erectile function through central mechanisms. Because dopamine inhibits prolactin, dopamine AGONIST drugs (cabergoline, bromocriptine) are the rational therapy: they restore inhibitory tone, normalize prolactin, and shrink lactotroph tumors.
Why men present late, and why that is dangerous
Women with prolactinomas often present early with menstrual disturbance or galactorrhea, prompting imaging while the tumor is small. Men lack that early signal: the symptoms (low libido, ED, fatigue) are nonspecific and easily mislabeled as 'low T', so male prolactinomas frequently grow into MACROADENOMAS before diagnosis. A large pituitary mass can compress the optic chiasm (bitemporal visual-field loss) and other pituitary axes. This is precisely why prolactin belongs in the low-libido/low-T workup: a man handed testosterone for 'low T' without a prolactin check can be carrying an enlarging, vision-threatening tumor. Also watch the assay 'hook effect', extremely high prolactin can paradoxically read falsely LOW on some immunoassays unless the sample is diluted.
What people get wrong
Often saidLow libido on normal testosterone just needs more testosterone
ActuallyPersistent low libido despite adequate testosterone should trigger a prolactin check; hyperprolactinemia is a discrete, treatable cause and can signal a pituitary tumor.
Often saidProlactinomas require surgery
ActuallyMost prolactinomas, even large ones, are treated MEDICALLY with dopamine agonists that shrink the tumor; surgery is second-line for resistant or intolerant cases.
Who profits, and who pushes back
Nobody is named here yet, because we have not done that work on this entry. Read that as unfinished. Somebody almost certainly sells this, and somebody almost certainly disputes it. Assume both until we have checked.
What we do not know
- What prolactin threshold best discriminates benign causes from tumor in asymptomatic men?
- What is the real valvulopathy risk at the lower cabergoline doses used for prolactinomas?
- How often is 'treatment-resistant low libido' in TRT practice actually unrecognized hyperprolactinemia?
At a glance
- Normal male prolactin
- Roughly <15-20 ng/mL (lab-dependent)
- Regulation
- Tonically INHIBITED by dopamine from the hypothalamus
- Male prolactinomas
- Often macroadenomas (>1 cm) at diagnosis
- First-line treatment
- Dopamine agonists (cabergoline preferred), not surgery
What this entry does not yet cover
What follows is unfinished work on our side, not a finding about Prolactin and Male Sexual Function. A short entry is not a safe entry.
- Timeline. We have not built the dated record of research and regulatory events.
- Cost and market. We have not documented what it sells for or who sells it.
- Supply chain. We have not mapped where it is made.
- Who uses it. We have not documented the user groups.
- What could change. No forward-looking summary yet.
- How it compares. We have not set it against the alternatives.
- Children and teenagers. We have not checked what is known about younger people.
Sources
The studies below are named and described, but not linked. You cannot open them from here and check our reading against them, which means this page is our summary of the literature rather than a document you can verify. Weigh it accordingly until the links exist.
The studies that matter
Endocrine Society Hyperprolactinemia Guideline (Melmed et al.)2011
Standardized the diagnosis of hyperprolactinemia and established dopamine agonists (cabergoline preferred) as first-line for prolactinomas, with surgery reserved for resistance/intolerance
Cabergoline vs bromocriptine trials1990s-2000s
Cabergoline more effective at normalizing prolactin and better tolerated; standard first choice
Pituitary Society macroadenoma consensus2000s-2010s
Dopamine agonists shrink most macroprolactinomas, often avoiding surgery even with chiasmal compression